Daniel Mekasha, MD
Pain Medicine · Southgate, MINPI 1003937798
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Acelrx Pharmaceuticals, Inc. accounts for 81.5% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $3,155 and has fallen 95.5% since, to $143 in 2025.
Across 30 payments — averaging $123.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acelrx Pharmaceuticals, Inc.$3K
- Boston Scientific$148
- UCB, Inc.$79
- EMD Serono, Inc.$76
- Pfizer$60
- AbbVie$56
- plus $263 from 9 others
What the payments were for
- Speaking & faculty fees$2,00054%
- Travel & lodging$73720%
- Food & beverage$92125%
- Education$381%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acelrx Pharmaceuticals, Inc. | 4 | $3,013 |
| Boston Scientific | 2 | $148 |
| UCB, Inc. | 3 | $79 |
| EMD Serono, Inc. | 3 | $76 |
| Pfizer | 3 | $60 |
| AbbVie | 3 | $56 |
| Pacira Pharmaceuticals Incorporated | 2 | $40 |
| Lilly USA, LLC | 2 | $38 |
| Merck | 2 | $38 |
| Lundbeck LLC | 1 | $31 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Eisai Inc. | 1 | $27 |
| SK Life Science, Inc. | 1 | $24 |
| Avanos Medical | 1 | $20 |
| Medtronic | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DSUVIA$3,013
- GENERAL PAIN MANAGEMENT$122
How this compares
$3,696 in reported general payments places this provider in the 60th percentile of 139 pain medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 25 | $166 |
| Gabapentin | 19 | $107 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Southgate
- Harry SukumaranRochester Hills$304K
- Nasir KhatriFlint$133K
- Yijia ChuGrand Rapids$88K
- Mark MounayerSouthfield$85K
- Jeffrey RosenbergCanton$44K
- Alexander TurfeWyandotte$41K
- Kendall GroseWyandotte$26K
- Craig HartrickRoyal Oak$26K
- Patrick ForrestAnn Arbor$23K
- Anmar DalatiDetroit$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.